section name header

Pronunciation

lyse-IN-oh-pril

Classifications

Therapeutic Classification: antihypertensives

Pharmacologic Classification: ace inhibitors

Indications

REMS


Action

  • Angiotensin-converting enzyme (ACE) inhibitors block the conversion of angiotensin I to the vasoconstrictor angiotensin II. ACE inhibitors also prevent the degradation of bradykinin and other vasodilatory prostaglandins. ACE inhibitors also plasma renin levels and aldosterone levels. Net result is systemic vasodilation.
Therapeutic effects:
  • Lowering of BP in hypertensive patients.
  • Increased survival and decreased symptoms in patients with HF.
  • Increased survival after MI.

Pharmacokinetics

Absorption: 25% absorbed following oral administration (much inter-individual variability).

Distribution: Crosses the placenta; may enter breast milk.

Metabolism/Excretion: 100% eliminated by the kidneys.

Half-Life: 12 hr ( in renal impairment).

Time/Action Profile

(effect on BP-single dose)
ROUTEONSETPEAKDURATION
PO1 hr6 hr24 hr



Full effects may not be noted for several weeks.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, chest pain

Derm: rash

F and E: hyperkalemia

GI: abdominal pain, diarrhea, nausea, vomiting

GU: erectile dysfunction, renal impairment

Neuro: dizziness, fatigue, headache, weakness

Resp: cough

Misc: ANGIOEDEMA

Interactions

Drug-drug:

Route/Dosage

Hypertension

Renal Impairment

Renal Impairment

Heart Failure

Renal Impairment

Acute Myocardial Infarction

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Prinivil, Qbrelis, Zestril

Pill Image

lisinopril_195-8748.jpg
lisinopril_195-8883.jpg

Code

NDC Code